Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kevin Trice

Sleep Medicine Louisville, KY Medical Doctor

NPI 1467548701 CMS profile 404777

3430 Newburg Rd Ste 150, Louisville, KY 40218

Open in the dashboard

General payments

$219,519

282 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$170,502 paid to institutions, not to them · program years 2022–2025

Through program year 2024, Kevin Trice of Louisville, KY is reported in the CMS Open Payments database as having received $219,519 across 282 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $170,502 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $82,940 86
2023 General $110,246 128
2022 General $25,091 46
2021 General $968 12
2020 General $186 5
2019 General $89 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Trice
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Kevin Trice were reported at $0. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year Kevin Trice Sleep Medicine median Middle half National median
2019 $89 $185 $66–$736 $163
2020 $186 $149 $46–$504 $114
2021 $968 $191 $62–$750 $132
2022 $25,091 $246 $92–$972 $149
2023 $110,246 $321 $119–$1,033 $160
2024 $82,940 $393 $111–$1,207 $164
2025 $0 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Jazz Pharmaceuticals Inc. $95,815 127 payments
  2. Avadel CNS Pharmaceuticals, LLC $60,289 49 payments
  3. Axsome Therapeutics, Inc. $40,111 40 payments
  4. Harmony Biosciences LLC $17,775 35 payments
  5. Idorsia Pharmaceuticals US Inc $3,212 9 payments
  6. Inspire Medical Systems, Inc. $1,509 10 payments
  7. AstraZeneca Pharmaceuticals LP $273 4 payments
  8. Regeneron Healthcare Solutions, Inc. $126 1 payment
  9. GlaxoSmithKline, LLC. $112 1 payment
  10. Amgen Inc. $100 1 payment
  11. Other $198 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $81,554 27 payments
  2. Honoraria $50,150 18 payments
  3. Consulting Fee $47,053 18 payments
  4. Travel and Lodging $29,540 68 payments
  5. Food and Beverage $9,818 146 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,275 1 payment
  7. Education $130 4 payments
Products named General payments · program years 2019–2024
  1. XYWAV $95,127 115 payments
  2. LUMRYZ $60,165 48 payments
  3. Sunosi $40,111 40 payments
  4. Wakix Neurological Disorders $7,364 15 payments
  5. WAKIX Sleep Medicine $5,945 13 payments
  6. WAKIX Narcoplepsy $4,466 7 payments
  7. QUVIVIQ $3,212 9 payments
  8. Inspire Upper Airway Stimulation System $1,146 3 payments
  9. XYREM $415 10 payments
  10. INSPIRE $362 7 payments
  11. Other $1,136 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record